The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress1 DEEs...
Hence then, the article about lundbeck to present new data on bexicaserin at upcoming congress highlighting long term impact on seizure frequency in patients with rare epilepsy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy )
Also on site :
- Road over canal in Penkridge closed as bridge reportedly collapses
- Disneyland Paris New Year’s Eve Fireworks Live Stream 2025–2026: Watch Here
- Police and air ambulance attend 'medical emergency' incident in Stourbridge